Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...

Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...

Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in ...

PROFITS from contraceptive pills used by the NHS are funding an organisation with close ties to Hungary’s hard-right government which ...

GET MORE AI-GENERATED SIGNALS: January 03, 2025, 16:08 pm ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a ...

Geode Capital Management LLC grew its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 0.7% during the third quarter, according to the company in its most recent filing with the ...